Read by QxMD icon Read

Cardiovascular Therapeutics

Kai Zhang, Zuowang Ma, Weiding Wang, Ruimeng Liu, Yue Zhang, Meng Yuan, Guangping Li
INTRODUCTION: Atrial remodeling in the form of fibrosis is considered as the substrate in the development of atrial fibrillation (AF). The aim of this study was to investigate the effects of tolvaptan on chronic intermittent hypoxia (CIH) induced atrial remodeling and the mechanisms underlying such changes. METHODS: A total of 45 Sprague-Dawley rats were randomized into three groups: Control group, CIH group, CIH with tolvaptan treatment (CIH-T) group (n = 15). CIH rats were subjected to CIH 6 h/d for 30 days, CIH-T rats were administrated tolvaptan while they received CIH...
September 11, 2018: Cardiovascular Therapeutics
Julio Núñez, Raquel Heredia, Ana Payá, Ignacio Sanchis, Susana Del Prado, Gema Miñana, Enrique Santas, Rafael de la Espriella, Eduardo Núñez, Juan Sanchis, Antoni Bayés-Genís
AIMS: Optimal diuretic treatment of patients with refractory congestive heart failure (CHF) remains to be elucidated. In this work, we aimed to evaluate the serial changes of functional class and surrogates of fluid overload (weight and antigen carbohydrate 125) after addition of oral acetazolamide in patients with refractory CHF. Likewise, serial changes in renal function, serum electrolytes and pH were evaluated. METHOD: This is an observational retrospective study in which 25 ambulatory patients with refractory CHF that received acetazolamide in addition to standard intensive diuretic strategy were evaluated...
September 6, 2018: Cardiovascular Therapeutics
Xiwen Qin, Joseph Hung, Matthew Knuiman, Tiew-Hwa K Teng, Tom Briffa, Frank M Sanfilippo
AIM: Hospitalized heart failure (HF) patients have a poor prognosis postdischarge. We determined whether renin-angiotensin system inhibitors (RASI) and β-blockers dispensed to patients within 60 days post-HF hospital discharge are associated with improved 1-year survival. METHODS: A retrospective population-based study was conducted in 4897 seniors, aged 65-84 years, alive at 60 days postindex HF hospitalization in Western Australia over 2003-2008. Dispensing of RASI and β-blocker dispensing was identified from the Pharmaceutical Benefits Scheme claims database linked to hospital admission and death records...
August 20, 2018: Cardiovascular Therapeutics
Ibrahim Al-Zakwani, Mohammad Zubaid, Alawi A Alsheikh-Ali, Wael Almahmeed, Wafa Rashed
AIM: To evaluate the prevalence and impact of the prescribing of an evidence-based cardiac medication (EBM) combination on 1-month, 6-months, and 12-months all-cause mortality in patients with acute coronary syndrome (ACS). METHODS: Data were analyzed from 3681 consecutive patients diagnosed with ACS admitted to 29 hospitals in 4 Middle Eastern countries from January 2012 to January 2013. The EBM combination consisted of concurrent prescribing of an antiplatelet therapy, angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB), β-blocker, and a statin, at hospital discharge...
August 6, 2018: Cardiovascular Therapeutics
Wei Gong, Youcai Ma, Aobo Li, Han Shi, Shaoping Nie
BACKGROUND/AIMS: Cardiac rupture (CR) is a catastrophic complication of acute myocardial infarction (MI). At present, there are no effective pharmacological strategies for preventing post-MI rupture. Here we investigated the effect of trimetazidine (TMZ) on post-MI CR. METHODS: MI models were induced by left coronary artery ligation in male C57BL/6 mice. Animals allocated to the rupture incidence were closely monitored for 7 days; autopsy was performed once animals were found dead to determine the reason of death...
July 17, 2018: Cardiovascular Therapeutics
Zeena Eblimit, Sundararajah Thevananther, Saul J Karpen, Heinrich Taegtmeyer, David D Moore, Luciano Adorini, Daniel J Penny, Moreshwar S Desai
INTRODUCTION: Administration of cholic acid, or its synthetic derivative, 6-alpha-ethyl-23(S)-methylcholic acid (INT-777), activates the membrane GPCR, TGR5, influences whole body metabolism, reduces atherosclerosis, and benefits the cardiovascular physiology in mice. Direct effects of TGR5 agonists, and the role for TGR5, on myocardial cell biology and stress response are unknown. METHODS: Mice were fed chow supplemented with 0.5% cholic acid (CA) or 0.025% INT-777, a specific TGR5 agonist, or regular chow for 3 weeks...
October 2018: Cardiovascular Therapeutics
Rong Yuan, Qiqi Xin, Weili Shi, Wei Liu, Simon-M Lee, Puiman Hoi, Lin Li, Jun Zhao, Weihong Cong, Keji Chen
AIM: It is not clear whether treatment by vascular endothelial growth factor (VEGF) gene transfer can improve myocardial ischemia through a proangiogenesis mechanism and is effective against coronary artery disease (CAD). We aimed to perform a systematic review and meta-analysis of randomized controlled trials (RCTs) that compared VEGF gene therapy and standard treatments in CAD. METHODS: We systematically searched the PubMed, Embase, and Cochrane databases and relevant references for RCTs (published up to May 2018; no language restrictions) and performed meta-analysis using both fixed and random effects models...
October 2018: Cardiovascular Therapeutics
Anna Jonsson, Helena Norberg, Ellinor Bergdahl, Krister Lindmark
AIM: Previous studies and national assessments indicate an undertreatment of mineralocorticoid receptor antagonists (MRA) in heart failure with reduced ejection fraction (HFrEF). This study aimed to investigate why MRA is not used to full extent. METHODS: A complete community-based heart failure population was studied. Several variables were collected, and medical records were scrutinized to identify reasons for not prescribing MRA. RESULTS: Of 2029 patients, 812 had EF ≤40%...
October 2018: Cardiovascular Therapeutics
Luca Zanella, Giacomo Zoppellaro, Lucia Marigo, Gentian Denas, Seena Padayattil Jose, Vittorio Pengo
BACKGROUND: Intracranial hemorrhage (ICH) is the most fearful side effect of oral anticoagulant therapy. It is still unclear which risk factor is involved in ICH during vitamin K antagonists (VKAs) treatment and if commonly used bleeding risk scores are able to predict ICH. PURPOSE: Search for individual risk factors and bleeding risk scores (HAS-BLED, ATRIA and ORBIT) associated with ICHs in patients with atrial fibrillation treated with VKAs. METHODS: This is a retrospective case-control study in a single Thrombosis Center...
October 2018: Cardiovascular Therapeutics
Zhen Ge, Michela Faggioni, Usman Baber, Samantha Sartori, Sabato Sorrentino, Serdar Farhan, Jaya Chandrasekhar, Birgit Vogel, Abdul Qadeer, Jonathan Halperin, Vivek Reddy, Srinivas Dukkipati, George Dangas, Roxana Mehran
AIMS: Catheter ablation for atrial fibrillation (AF) is associated with a transitory increase in the risk of both thromboembolic and bleeding events. Evidence on the use of nonvitamin K antagonist oral anticoagulants (NOACs) in patients undergoing AF ablation mostly comes from small observational studies, underpowered to detect differences in clinical outcomes between NOACs and vitamin K antagonists (VKAs) treated patients. This updated meta-analysis aimed to determine the safety and efficacy of periprocedural anticoagulation with NOACs compared with VKAs in AF patients undergoing catheter ablation...
October 2018: Cardiovascular Therapeutics
Vasilios G Athyros, Niki Katsiki, Dimitri P Mikhailidis
No abstract text is available yet for this article.
October 2018: Cardiovascular Therapeutics
Monica Teng, Ying Jiao Zhao, Ai Leng Khoo, Rajiv Ananthakrishna, Tiong Cheng Yeo, Boon Peng Lim, Mark Y Chan, Joshua P Loh
AIM: Compared with second-generation durable polymer drug-eluting stents (DP-DES), the cost-effectiveness of biodegradable polymer drug-eluting stents (BP-DES) remains unclear in the real-world setting. We assessed the cost-effectiveness of BP-DES in patients with coronary artery disease undergoing percutaneous coronary intervention (PCI). METHODS: We developed a decision-analytic model to compare the cost-effectiveness of BP-DES to DP-DES over 1 year and 5 years from healthcare payer perspective...
October 2018: Cardiovascular Therapeutics
Yaling Han, Jiyan Chen, Miaohan Qiu, Yi Li, Jing Li, Yingqing Feng, Jian Qiu, Liang Meng, Yihong Sun, Guizhou Tao, Zhaohui Wu, Chunyu Yang, Jincheng Guo, Kui Pu, Shaoliang Chen, Xiaozeng Wang
BACKGROUND: The prognosis of patients with coronary artery disease (CAD) at hospital discharge was constantly varying, and postdischarge risk of ischemic events remain a concern. However, risk prediction tools to identify risk of ischemia for these patients has not yet been reported. AIMS: We sought to develop a scoring system for predicting long-term ischemic events in CAD patients receiving antiplatelet therapy that would be beneficial in appropriate personalized decision-making for these patients...
October 2018: Cardiovascular Therapeutics
Barak Zafrir, Ayman Jubran
AIM: PCSK9 inhibitors (PCSK9i) effectively lower cholesterol levels in randomized trials with reduction in cardiovascular outcomes and favorable safety profile. However, the access to PCSK9i is limited due to high cost and data regarding the use of PCSK9i in real-world practice is limited. METHODS: Data on all patients submitted for approval of PCSK9i at a regional lipid clinic, outside of clinical trials. Patients' profile, approval rates, low-density lipoprotein cholesterol (LDL-C) reduction rates, and adverse events were evaluated...
October 2018: Cardiovascular Therapeutics
Pei Zhu, Xiaofang Tang, Jingjing Xu, Ying Song, Ru Liu, Yin Zhang, Lijian Gao, Zhan Gao, Jue Chen, Yuejin Yang, Runlin Gao, Bo Xu, Jinqing Yuan
AIM: To evaluate the incidence, predictors, and outcomes of postdischarge gastrointestinal bleeding (GIB) in patients underwent percutaneous coronary intervention (PCI) in a 2-year follow-up study. METHODS AND RESULTS: All consecutive patients who underwent PCI throughout 2013 were enrolled. Multivariable cox proportional hazards regression were used to identify predictors of postdischarge GIB and 2-year major adverse cardiovascular and cerebrovascular events (MACCE)...
October 2018: Cardiovascular Therapeutics
(no author information available yet)
No abstract text is available yet for this article.
August 2018: Cardiovascular Therapeutics
Marcello Rattazzi, Elisabetta Faggin, Elisa Bertacco, Chiara Nardin, Leopoldo Pagliani, Mario Plebani, Francesco Cinetto, Diego Guidolin, Massimo Puato, Paolo Pauletto
INTRODUCTION: Vitamin K antagonists, such as warfarin, are known to promote arterial calcification through blockade of gamma-carboxylation of Matrix-Gla-Protein. It is currently unknown whether other oral anticoagulants such as direct inhibitors of Factor Xa can have protective effects on the progression of aortic valve calcification. AIMS: To compare the effect of warfarin and rivaroxaban on the progression of aortic valve calcification in atherosclerotic mice...
August 2018: Cardiovascular Therapeutics
Ningning Tang, Shaoyan Jiang, Yanyan Yang, Shaoyan Liu, Murugavel Ponnusamy, Hui Xin, Tao Yu
Atherosclerosis is one of the major macrovascular complications of diabetes mellitus (DM), and it is the main cause of death from clinical observation. Among various cell types involved in this disorder, endothelial cells, vascular smooth muscle cells (VSMCs), and macrophages play a crucial role in the occurrence and development of this disease. The regulation and stabilization of these cells are a key therapeutic strategy for DM-associated atherosclerosis. An increasing number of evidences implicate that various types of noncoding RNAs (ncRNAs) play a vital role in many cellular responses as well as in physiological and pathological processes of atherosclerosis and DM that drive atherogenic/antiatherogenic processes in those cells...
August 2018: Cardiovascular Therapeutics
Zhengqin Zhai, Shuang Zhao, Min Tang, Liujun Jia, Shu Zhang
AIM: Median nerve stimulation (MNS) is a novel neuromodulation approach for treatment of ventricular arrhythmia, but little is known about its chronic effects. The aim of this study was to investigate the effects of chronic MNS on ventricular arrhythmia and ventricular dysfunction postmyocardial infarction (MI). METHOD: Two weeks after MI, 12 rabbits were randomly divided into control and MNS groups, and chronic MNS was performed in MNS group for 2 weeks. Ventricular function and arrhythmias; sympathetic innervation and activity; and interleukin-1 β (IL-1 β) and norepinephrine (NE) levels were analyzed...
August 2018: Cardiovascular Therapeutics
Pieter Martens, Hanne Beliën, Matthias Dupont, Pieter Vandervoort, Wilfried Mullens
BACKGROUND: Major classes of medical therapy for heart failure with reduced ejection fraction (HFrEF) induce reverse remodeling. The revere remodeling response to sacubitril/valsartan remains unstudied. METHODS: We performed a single-center, prospective assessor-blinded study to determine the reverse remodeling response of sacubitril/valsartan therapy in HFrEF patients with a class I indication (New York heart Association [NYHA]-class II-IV, Left ventricular ejection fraction [LVEF] < 35%, optimal dose with Renin-Angiotensin-System-Blocker [RAS-blocker])...
August 2018: Cardiovascular Therapeutics
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"